FRANKFURT, March 22 (Reuters) - A key German drug

reimbursement body has said that regulation banning the nation's

health insurance system from paying for weight-loss drugs such

as Wegovy will not apply in the case of other approved uses of

the weekly injection.

The guidance, posted online late on Thursday by health

agency G-BA for Europe's largest national drug market, is among

the first signs that a push by drugmaker Novo Nordisk

to widen insurance coverage in Europe - by showing health

benefits beyond weight loss - is working out.

The European Union's drug regulator has been reviewing wider

use of highly popular Wegovy to include reducing the risk of

strokes and heart attacks, adding to the previously-approved use

to tackle obesity.